

CLINICAL VIGNETTE

A Case of Metastatic Salivary Gland Carcinoma in Patient with NSCLC

Mana Khafaf, MD and Katharine Borthwick, MD

An 85-year-old gentleman with known metastatic right lung adenocarcinoma requiring lobectomy the year prior, presented with a new left sided facial droop, rhinorrhea, and burning sensation in his left eye. The patient had a significant smoking history but had quit 40 years ago. He also had a history of alcohol use and extensive vascular disease including chronic aortic dissection and prior strokes. He was evaluated by Neurology and Ophthalmology for his new left sided findings. An MRI of the brain and internal auditory canals four months after onset of symptoms was normal and he was diagnosed with Bell's palsy.

Over the next seven months, his left-sided facial and eyelid droop worsened and began to interfere with his vision. He was referred for a possible ptosis surgery, however, the preoperative MRI revealed a T1 hypointense enhancing mass within the left parotid gland concerning for a primary salivary gland neoplasm. The entire left parotid gland demonstrated increased T2 signal and hazy enhancement concerning for infiltrative tumor. A prominent enhancing 0.9 cm posterior left cervical lymph node was concerning for nodal metastasis.

Subsequent CT with Positron Emission Tomography (PET/CT) showed a moderate to intense metabolically active nodule deep in the left parotid gland compatible with neoplasm. Moderate active lymph nodes in the left lateral neck and in the posterior triangle region were suspicious for lymph node metastasis. Innumerable bilateral lung nodules consistent with neoplastic lesions were also noted.

A left lymph node biopsy showed parotid adenocarcinoma which was AR and HER2 positive. The patient was diagnosed with a primary salivary duct adenocarcinoma with metastasis to the lung.

He completed radiation therapy to the left parotid and neck region followed by Herceptin.

Surveillance PET/CT scan six months after his initial PET/CT showed interval resolution of a previously noted left parotid mass with no discrete soft tissue abnormality.

Background

Salivary gland tumors are not common and consist of about 6-8% of head and neck tumors.

The parotid gland is the most common site of all salivary gland tumors, consisting of about 80-85% of the cases.^{1,2} About three quarters of parotid gland tumors are benign which leaves about 25% of them malignant.³

Compared to parotid gland tumors, about 40-45% of sub-mandibular gland tumors, 70-90% of sublingual gland tumors and 5-75% of minor salivary gland tumors are malignant.

About half of all salivary tumors are pleomorphic adenomas, which are the most common benign salivary gland tumor. Mucoepidermoid carcinoma and adenoid cystic carcinoma consist about 50% of all malignant salivary gland tumors.⁴⁻⁶

Risk Factors

Several risk factors are associated with salivary gland tumors. Radiation exposure seems to correlate with both malignant and benign salivary gland tumors, based on data from Atomic bomb survivors in Japan.⁷ Patients who received long-term radiation therapy for malignancy such as Hodgkin lymphoma are also at increased risk.^{8,9} Smoking is another risk factor which is more associated with Warthin tumor.^{10,11} Viral infections such as Epstein Barr Virus (EBV), Human immunodeficiency virus (HIV) and high-risk serotypes of Human Papilloma Virus (HPV) have also been associated with increased risk for salivary gland tumors as well.¹²⁻¹⁵

Other environmental and industrial exposures include: rubber manufacturing, hairdressing, and working with nickel compounds.^{16,17}

Clinical Presentation

Clinical presentation largely depends on the site of origin and associated involvement of nearby structures.

Major salivary gland tumors usually have a painless presentation. Malignant tumors present more frequently with signs or symptoms of facial nerve involvement or paralysis compared to the benign ones.¹⁸ Tumors with high malignancy potential have more likelihood of lymph node spread with intra-parotid lymph nodes being the initial site.⁴ Lungs, bone and liver are the most frequent sites of distant metastases.¹⁴ Metastases can be discovered even 10 to 20 years after treatment of more malignant lesions such as adenoid cystic carcinoma.⁵

Differential Diagnosis

The differential diagnosis of enlarged salivary glands include: salivary cysts, cysts of the first brachial cleft, salivary gland stones, Sjogren syndrome, metastases from other sites, lympho-epithelial cysts, chronic sclerosing sialadenitis and lymphadenopathy from infection, inflammation, or malignancy. Less common causes of facial nerve paralysis include sarcoid infiltration of the parotid gland and intra-parotid facial nerve schwannoma.¹⁵

Presence of other neurological abnormalities or failure of improvement of the symptoms within a predicted time can distinguish Bell's palsy from malignant parotid tumors.¹⁹

Assessment

Physical exam should concentrate on mass size and focus on any underlying mobility or fixation of the mass to underlying structures. Evaluation of any areas of tenderness, limitations in jaw movements and any associated lymphadenopathy particularly in the cervical nodes should be documented. Evaluation should also include an assessment for any possible primary source of malignancy.²⁰

Imaging

Both CT scan and MRI imaging are used to differentiate benign from malignant lesions as well as identify the degree of extension into surrounding tissues and the possible site of nodal/systemic metastases.^{21,22} Bony lesions, including those in the temporal or mandibular bone, are best identified by CT. Soft tissue infiltration, peri-neural invasion and intracranial extension can be evaluated in more detail by MRI.²³ Regional lymph nodes and distant metastases can be accurately evaluated by PET imaging with flurodeoxyglucose (FDG).²⁴⁻²⁶

Ultrasound may be a timelier and more cost-effective initial mode of imaging and can be utilized in fine needle aspiration (FNA) and core needle biopsy procedures.²⁷⁻³⁰ Of note, since Warthin tumor has a tendency for multifocality, both parotid glands should be imaged.³¹

Diagnosis

Salivary tumors will ultimately require a tissue diagnosis to differentiate between benign versus malignant tumors or lymphoma. Subsequent treatment plan will depend on the biopsy results.² Both ultrasound- guided fine needle aspiration and core needle biopsy are considered safe and simple in the evaluation of these tumors.^{32,33}

REFERENCES

1. **El-Naggar AK, Chan JKC, Grandis JR, Takata T, Slootweg PJ**, eds. *WHO Classification of Tumors of Head and Neck*, IARC, Lyon 2017.
2. **Guzzo M, Locati LD, Prott FJ, Gatta G, McGurk M, Licitra L**. Major and minor salivary gland tumors. *Crit Rev Oncol Hematol*. 2010 May;74(2):134-48. doi: 10.1016/j.critrevonc.2009.10.004. Epub 2009 Nov 24. PMID: 19939701.
3. **Spiro RH**. Salivary neoplasms: overview of a 35-year experience with 2,807 patients. *Head Neck Surg*. 1986 Jan-Feb;8(3):177-84. doi: 10.1002/hed.2890080309. PMID: 3744850.
4. **Xiao CC, Zhan KY, White-Gilbertson SJ, Day TA**. Predictors of Nodal Metastasis in Parotid Malignancies: A National Cancer Data Base Study of 22,653 Patients. *Otolaryngol Head Neck Surg*. 2016 Jan;154(1):121-30. doi: 10.1177/0194599815607449. Epub 2015 Sep 29. PMID: 26419838.
5. **Dillon PM, Chakraborty S, Moskaluk CA, Joshi PJ, Thomas CY**. Adenoid cystic carcinoma: A review of recent advances, molecular targets, and clinical trials. *Head Neck*. 2016 Apr;38(4):620-7. doi: 10.1002/hed.23925. Epub 2015 Jun 16. PMID: 25487882; PMCID: PMC6166139.
6. **Hay AJ, Migliacci J, Karassawa Zanoni D, McGill M, Patel S, Ganly I**. Minor salivary gland tumors of the head and neck-Memorial Sloan Kettering experience: Incidence and outcomes by site and histological type. *Cancer*. 2019 Oct 1;125(19):3354-3366. doi: 10.1002/cncr.32208. Epub 2019 Jun 7. PMID: 31174233; PMCID: PMC6744325.
7. **Saku T, Hayashi Y, Takahara O, Matsuura H, Tokunaga M, Tokunaga M, Tokuoka S, Soda M, Mabuchi K, Land CE**. Salivary gland tumors among atomic bomb survivors, 1950-1987. *Cancer*. 1997 Apr 15;79(8):1465-75. PMID: 9118025.
8. **Boukheris H, Ron E, Dores GM, Stovall M, Smith SA, Curtis RE**. Risk of radiation-related salivary gland carcinomas among survivors of Hodgkin lymphoma: a population-based analysis. *Cancer*. 2008 Dec 1;113(11):3153-9. doi: 10.1002/cncr.23918. PMID: 18823043; PMCID: PMC2868333.
9. **Chowdhry AK, McHugh C, Fung C, Dhakal S, Constine LS, Milano MT**. Second primary head and neck cancer after Hodgkin lymphoma: a population-based study of 44,879 survivors of Hodgkin lymphoma. *Cancer*. 2015 May 1;121(9):1436-45. doi: 10.1002/cncr.29231. Epub 2015 Jan 8. PMID: 25572913.
10. **Pinkston JA, Cole P**. Cigarette smoking and Warthin's tumor. *Am J Epidemiol*. 1996 Jul 15;144(2):183-7. doi: 10.1093/oxfordjournals.aje.a008906. PMID: 8678050.
11. **de Ru JA, Plantinga RF, Majoer MH, van Benthem PP, Slootweg PJ, Peeters PH, Hordijk GJ**. Warthin's tumour and smoking. *B-ENT*. 2005;1(2):63-6. PMID: 16044736.
12. **Serraino D, Boschini A, Carrieri P, Pradier C, Dorrucchi M, Dal Maso L, Ballarini P, Pezzotti P, Smacchia C, Pesce A, Ippolito G, Franceschi S, Rezza G**. Cancer risk among men with, or at risk of, HIV infection in southern Europe. *AIDS*. 2000 Mar 31;14(5):553-9. doi: 10.1097/00002030-200003310-00011. PMID: 10780718.
13. **Shebl FM, Bhatia K, Engels EA**. Salivary gland and nasopharyngeal cancers in individuals with acquired

- immunodeficiency syndrome in United States. *Int J Cancer*. 2010 May 15;126(10):2503-8. doi: 10.1002/ijc.24930. PMID: 19810095; PMCID: PMC2847048.
14. **Licitra L, Grandi C, Prott FJ, Schornagel JH, Bruzzi P, Molinari R.** Major and minor salivary glands tumours. *Crit Rev Oncol Hematol*. 2003 Feb;45(2):215-25. doi: 10.1016/s1040-8428(02)00005-7. PMID: 12604131.
 15. **Caughey RJ, May M, Schaitkin BM.** Intraparotid facial nerve schwannoma: diagnosis and management. *Otolaryngol Head Neck Surg*. 2004 May;130(5):586-92. doi: 10.1016/j.otohns.2003.12.011. PMID: 15138425.
 16. **Horn-Ross PL, Ljung BM, Morrow M.** Environmental factors and the risk of salivary gland cancer. *Epidemiology*. 1997 Jul;8(4):414-9. doi: 10.1097/00001648-199707000-00011. PMID: 9209856.
 17. **Swanson GM, Burns PB.** Cancers of the salivary gland: workplace risks among women and men. *Ann Epidemiol*. 1997 Aug;7(6):369-74. doi: 10.1016/s1047-2797(97)00041-0. PMID: 9279445.
 18. **Schramm VL Jr, Imola MJ.** Management of nasopharyngeal salivary gland malignancy. *Laryngoscope*. 2001 Sep;111(9):1533-44. doi: 10.1097/00005537-200109000-00009. PMID: 11568602.
 19. **Quesnel AM, Lindsay RW, Hadlock TA.** When the bell tolls on Bell's palsy: finding occult malignancy in acute-onset facial paralysis. *Am J Otolaryngol*. 2010 Sep-Oct;31(5):339-42. doi: 10.1016/j.amjoto.2009.04.003. Epub 2009 Jun 24. PMID: 20015776.
 20. **Pynnonen MA, Gillespie MB, Roman B, Rosenfeld RM, Tunkel DE, Bontempo L, Brook I, Chick DA, Colandrea M, Finestone SA, Fowler JC, Griffith CC, Henson Z, Levine C, Mehta V, Salama A, Scharpf J, Shatzkes DR, Stern WB, Youngerman JS, Corrigan MD.** Clinical Practice Guideline: Evaluation of the Neck Mass in Adults. *Otolaryngol Head Neck Surg*. 2017 Sep;157(2_suppl):S1-S30. doi: 10.1177/0194599817722550. PMID: 28891406.
 21. **Lee YY, Wong KT, King AD, Ahuja AT.** Imaging of salivary gland tumours. *Eur J Radiol*. 2008 Jun;66(3):419-36. doi: 10.1016/j.ejrad.2008.01.027. Epub 2008 Mar 11. PMID: 18337041.
 22. **Hisatomi M, Asaumi J, Yanagi Y, Unetsubo T, Maki Y, Murakami J, Matsuzaki H, Honda Y, Konouchi H.** Diagnostic value of dynamic contrast-enhanced MRI in the salivary gland tumors. *Oral Oncol*. 2007 Oct;43(9):940-7. doi: 10.1016/j.oraloncology.2006.11.009. Epub 2007 Jan 25. PMID: 17257881.
 23. **Koyuncu M, Seşen T, Akan H, Ismailoglu AA, Tanyeri Y, Tekat A, Unal R, Incesu L.** Comparison of computed tomography and magnetic resonance imaging in the diagnosis of parotid tumors. *Otolaryngol Head Neck Surg*. 2003 Dec;129(6):726-32. doi: 10.1016/j.otohns.2003.07.009. PMID: 14663442.
 24. **Cermik TF, Mavi A, Acikgoz G, Houseni M, Dadparvar S, Alavi A.** FDG PET in detecting primary and recurrent malignant salivary gland tumors. *Clin Nucl Med*. 2007 Apr;32(4):286-91. doi: 10.1097/01.rlu.0000257336.69537.cb. PMID: 17413575.
 25. **Razfar A, Heron DE, Branstetter BF 4th, Seethala RR, Ferris RL.** Positron emission tomography-computed tomography adds to the management of salivary gland malignancies. *Laryngoscope*. 2010 Apr;120(4):734-8. doi: 10.1002/lary.20829. PMID: 20213798.
 26. **Kim MJ, Kim JS, Roh JL, Lee JH, Cho KJ, Choi SH, Nam SY, Kim SY.** Utility of 18F-FDG PET/CT for detecting neck metastasis in patients with salivary gland carcinomas: preoperative planning for necessity and extent of neck dissection. *Ann Surg Oncol*. 2013 Mar;20(3):899-905. doi: 10.1245/s10434-012-2716-5. Epub 2012 Nov 19. PMID: 23161114.
 27. **Kotecha S, Bhatia P, Rout PG.** Diagnostic ultrasound in the head and neck region. *Dent Update*. 2008 Oct;35(8):529-30, 533-4. doi: 10.12968/denu.2008.35.8.529. PMID: 19055089.
 28. **Koischwitz D, Gritzmann N.** Ultrasound of the neck. *Radiol Clin North Am*. 2000 Sep;38(5):1029-45. doi: 10.1016/s0033-8389(05)70219-0. PMID: 11054967.
 29. **Bialek EJ, Jakubowski W, Karpińska G.** Role of ultrasonography in diagnosis and differentiation of pleomorphic adenomas: work in progress. *Arch Otolaryngol Head Neck Surg*. 2003 Sep;129(9):929-33. doi: 10.1001/archotol.129.9.929. PMID: 12975263.
 30. **Feld R, Nazarian LN, Needleman L, Lev-Toaff AS, Segal SR, Rao VM, Bibbo M, Lowry LD.** Clinical impact of sonographically guided biopsy of salivary gland masses and surrounding lymph nodes. *Ear Nose Throat J*. 1999 Dec;78(12):905, 908-12. PMID: 10624054.
 31. **van Tongeren J, Creyten DH, Meulemans EV, de Bondt RB, de Jong J, Manni JJ.** Synchronous bilateral epithelial-myoepithelial carcinoma of the parotid gland: case report and review of the literature. *Eur Arch Otorhinolaryngol*. 2009 Sep;266(9):1495-500. doi: 10.1007/s00405-008-0824-4. Epub 2008 Oct 8. PMID: 18841376; PMCID: PMC2718197.
 32. **Christensen RK, Bjørndal K, Godballe C, Krogdahl A.** Value of fine-needle aspiration biopsy of salivary gland lesions. *Head Neck*. 2010 Jan;32(1):104-8. doi: 10.1002/hed.21151. PMID: 19459210.
 33. **Liu CC, Jethwa AR, Khariwala SS, Johnson J, Shin JJ.** Sensitivity, Specificity, and Posttest Probability of Parotid Fine-Needle Aspiration: A Systematic Review and Meta-analysis. *Otolaryngol Head Neck Surg*. 2016 Jan;154(1):9-23. doi: 10.1177/0194599815607841. Epub 2015 Oct 1. PMID: 26428476; PMCID: PMC4896151.